Therapeutic potential of targeting SIRT1 for the treatment of Alzheimer's disease.
- Author:
Li-Li SHEN
1
;
Hui-Yan SUN
2
;
Hong-Quan WANG
3
Author Information
1. Department of Neurology, The Affiliated Hospital of Chifeng University, Chifeng 024005, China.
2. Chifeng University Health Science Center, Chifeng 024000, China.
3. Department of Neurology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Alzheimer Disease;
Amyloid beta-Protein Precursor;
Animals, Genetically Modified;
Sirtuin 1;
Sirtuins;
Humans
- From:
Acta Physiologica Sinica
2023;75(1):99-107
- CountryChina
- Language:Chinese
-
Abstract:
Silent information regulator 1 (SIRT1) is one of the seven mammalian proteins of the sirtuin family of NAD+-dependent deacetylases. SIRT1 plays a pivotal role in neuroprotection and ongoing research has uncovered a mechanism by which SIRT1 may exert a neuroprotective effect on Alzheimer's disease (AD). Growing evidence demonstrates that SIRT1 regulates many pathological processes including amyloid-β precursor protein (APP) processing, neuroinflammation, neurodegeneration, and mitochondrial dysfunction. SIRT1 has recently received enormous attention, and pharmacological or transgenic approaches to activate the sirtuin pathway have shown promising results in the experimental models of AD. In the present review, we delineate the role of SIRT1 in AD from a disease-centered perspective and provides an up-to-date overview of the SIRT1 modulators and their potential as effective therapeutics in AD.
